% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pajtler:130295,
      author       = {K. Pajtler$^*$ and S. Tippelt and N. Siegler and S.
                      Reichling and M. Zimmermann and R. Mikasch and U. Bode and
                      A. Gnekow and T. Pietsch and M. Benesch and S. Rutkowski and
                      G. Fleischhack},
      title        = {{I}ntraventricular etoposide safety and toxicity profile in
                      children and young adults with refractory or recurrent
                      malignant brain tumors.},
      journal      = {Journal of neuro-oncology},
      volume       = {128},
      number       = {3},
      issn         = {1573-7373},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {DKFZ-2017-05374},
      pages        = {463 - 471},
      year         = {2016},
      abstract     = {Systemic administration of etoposide is effective in
                      treating metastatic, recurrent or refractory brain tumors,
                      but penetration into the cerebrospinal fluid is extremely
                      poor. This study was designed to determine the safety and
                      toxicity profile of intraventricular etoposide
                      administration and was affiliated with the prospective,
                      multicenter, nonblinded, nonrandomized, multi-armed
                      HIT-REZ-97 trial. The study enrolled 68 patients, aged
                      1.1-34.6 (median age 11 years). Adverse events that could
                      possibly be related to intraventricular etoposide therapy
                      were documented and analyzed. Intraventricular etoposide was
                      simultaneously administered with either oral or intravenous
                      chemotherapy in 426 courses according to three major
                      schedules varying in dosing (0.25-1 mg), frequency of
                      administration (bolus injection, every 12 or 24 h), course
                      duration (5-10 days) and length of interval between courses
                      (2-5 weeks). Potential treatment-related adverse effects
                      included transient headache, seizures, infection of the
                      reservoir, nausea and neuropsychological symptoms.
                      Hematological side effects were not observed. One patient,
                      with history of multiple prior therapies, who received
                      long-term intraventricular and oral etoposide treatment
                      developed acute myeloid leukemia as a secondary malignancy.
                      Overall intraventricular etoposide is well tolerated. The
                      results of this study have warranted a phase II trial to
                      determine the effectiveness of this regimen in disease
                      stages with very limited therapeutic options.},
      cin          = {B062},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27147083},
      doi          = {10.1007/s11060-016-2133-x},
      url          = {https://inrepo02.dkfz.de/record/130295},
}